MARKET

SYRS

SYRS

Syros Pharmaceut
NASDAQ
5.23
-0.12
-2.15%
Opening 10:22 06/20 EDT
OPEN
5.33
PREV CLOSE
5.34
HIGH
5.36
LOW
5.17
VOLUME
12.12K
TURNOVER
0
52 WEEK HIGH
8.17
52 WEEK LOW
2.090
MARKET CAP
139.66M
P/E (TTM)
-1.0436
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SYRS last week (0610-0614)?
Weekly Report · 3d ago
Weekly Report: what happened at SYRS last week (0603-0607)?
Weekly Report · 06/10 09:01
Syros Pharmaceuticals’ Shareholders Approve Key Updates and Elections
TipRanks · 06/06 21:16
Weekly Report: what happened at SYRS last week (0527-0531)?
Weekly Report · 06/03 09:01
Weekly Report: what happened at SYRS last week (0520-0524)?
Weekly Report · 05/27 09:01
Weekly Report: what happened at SYRS last week (0513-0517)?
Weekly Report · 05/20 09:01
Syros Pharmaceuticals Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 05/15 11:05
Optimistic Outlook for Syros Pharmaceuticals with Promising Clinical Trials and Regulatory Advancements
In a report released today, Andrew Fein from Wainwright reiterated a Buy rating on Syros Pharmaceuticals. The company is developing treatments for cancer and other diseases. The FDA has granted Fast Track Designation to the tamibarotene treatment for acute myeloid leukemia.
TipRanks · 05/15 10:28
More
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).

Webull offers Syros Pharmaceuticals Inc stock information, including NASDAQ: SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.